JNJ

#20
Johnson & Johnson Common Stock
227.8 1 USD
-1.33%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
227.72
231.48
Range Annuel
149.04
251.71
Changement quotidien
-1.33%
Changement Mensuel
-0.05%
Evolution sur 6 mois
+10.45%
Changement Annuel
+48.02%
Clôture Précédente
230.8 7
Open
230.8 8
Low
227.7 2
High
231.4 8
Volume
682
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 548.39 B
  • Employee 141 K
  • Founded N/A
  • CEO Joaquin Duato
  • Website www.jnj.com
  • Headquarter New Jersey, United States
  • FIGI BBG000BMHYD1
  • Industry Fabricants de Médicaments — Généralités
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
18.82
ratio cours/chiffre d'affaires
5.35
Dividende par action
5.14
Rendement du dividende (%)
2.48

Johnson & Johnson Common Stock

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments. The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.

Nouvelles